Limitations of C2 monitoring in renal transplant recipients.
BACKGROUND
Recent developments have proposed the cyclosporin (CsA) concentration at 2 h post-dose (C(2)) as the best single time-point predictor of the extent of CsA exposure and as the optimal basis for monitoring immunosuppressive therapy in renal transplant patients. The present study sought to validate the cornerstones of the current concept of C(2) monitoring.


METHODS
We assessed the predictive value, dose proportionality and intrapatient variability of C(2) levels in 41 de novo renal transplant recipients treated with CsA microemulsion, steroids, mycophenolate sodium and basiliximab.


RESULTS
Patients with rejection and patients with CsA nephrotoxicity had lower C(2) (P = NS) and absorption (P<0.05 for toxicity), while C(0) did not show any significant difference. Receiver operating characteristic analysis did not detect discriminative C(2) values as a predictor of rejection or toxicity. In a substantial number of patients (29%) we observed poor and/or slow absorption, with C(0) >300 ng/ml and C(2) levels <800 ng/ml during the first month and a high rate of complications in these patients (18% rejection, 64% toxicity). Absorption increased over the first month post-transplant. Analysis of dose changes indicated that C(2) levels are not dose-proportional. Intrapatient variability of C(2) was as high as that of C(0).


CONCLUSIONS
C(2) levels do not predict rejection or toxicity. C(2) monitoring alone does not detect toxicity in poor and/or slow absorbers, who constitute a significant proportion of patients. Changes in absorption over time, high intrapatient variability and lack of dose proportionality constitute further limitations of the C(2) monitoring concept in the early post-transplant phase.
Einecke
Gunilla
G
Department of Nephrology, Charité, Berlin, Germany. gunilla.einecke@ualberta.ca
Schütz
Manuela
M
Mai
Ingrid
I
Fritsche
Lutz
L
Giessing
Markus
M
Glander
Petra
P
Neumayer
Hans-H
HH
Budde
Klemens
K
D000328:Adult; D016572:Cyclosporine / Q000008:administration & dosage / Q000097:blood* / Q000493:pharmacokinetics; D004305:Dose-Response Relationship, Drug; D016903:Drug Monitoring; D005260:Female; D006084:Graft Rejection / Q000097:blood*; D006085:Graft Survival / Q000502:physiology; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000097:blood* / Q000493:pharmacokinetics; D007674:Kidney Diseases / Q000097:blood* / Q000139:chemically induced / Q000601:surgery; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D013997:Time Factors
D007166:Immunosuppressive Agents; D016572:Cyclosporine